Modelling the natural history of Huntington's disease progression

被引:13
|
作者
Kuan, W. L. [1 ]
Kasis, A. [2 ]
Yuan, Y. [2 ]
Mason, S. L. [1 ]
Lazar, A. S. [1 ]
Barker, R. A. [1 ]
Goncalves, J. [2 ,3 ]
机构
[1] Univ Cambridge, Dept Clin Neurosci, John van Geest Ctr Brain Repair, Cambridge, England
[2] Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England
[3] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Walferdange, Belval, Luxembourg
来源
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2015年 / 86卷 / 10期
基金
英国工程与自然科学研究理事会;
关键词
CAG-REPEAT LENGTH; AGE-OF-ONSET; NEURODEGENERATIVE DISEASES; CLINICAL PROGRESSION; RATING-SCALE;
D O I
10.1136/jnnp-2014-308153
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The lack of reliable biomarkers to track disease progression is a major problem in clinical research of chronic neurological disorders. Using Huntington's disease (HD) as an example, we describe a novel approach to model HD and show that the progression of a neurological disorder can be predicted for individual patients. Methods Starting with an initial cohort of 343 patients with HD that we have followed since 1995, we used data from 68 patients that satisfied our filtering criteria to model disease progression, based on the Unified Huntington's Disease Rating Scale (UHDRS), a measure that is routinely used in HD clinics worldwide. Results Our model was validated by: (A) extrapolating our equation to model the age of disease onset, (B) testing it on a second patient data set by loosening our filtering criteria, (C) cross-validating with a repeated random subsampling approach and (D) holdout validating with the latest clinical assessment data from the same cohort of patients. With UHDRS scores from the past four clinical visits (over a minimum span of 2 years), our model predicts disease progression of individual patients over the next 2 years with an accuracy of 89-91%. We have also provided evidence that patients with similar baseline clinical profiles can exhibit very different trajectories of disease progression. Conclusions This new model therefore has important implications for HD research, most obviously in the development of potential disease-modifying therapies. We believe that a similar approach can also be adapted to model disease progression in other chronic neurological disorders.
引用
收藏
页码:1143 / 1149
页数:7
相关论文
共 50 条
  • [21] On the pathological progression of Huntington's disease - Reply
    Penney, JB
    VonSattel, JP
    MacDonald, ME
    Gusella, JF
    Myers, RH
    ANNALS OF NEUROLOGY, 1998, 44 (01) : 149 - 149
  • [22] Genetics, history, and Huntington's disease
    Harper, PS
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [23] Data-driven Huntington's disease progression modelling and estimation of societal cost in the UK
    Pollard, Andrew
    Greetham, Danica
    Myatt, James
    Rickards, Hugh
    Stanley, Cath
    Dungate, Dave
    ROYAL SOCIETY OPEN SCIENCE, 2024, 11 (11):
  • [24] Experience of experimental modelling of Huntington’s disease
    Stavrovskaya A.V.
    Voronkov D.N.
    Yamshchikova N.G.
    Ol’shanskiy A.S.
    Khudoerkov R.M.
    Illarioshkin S.N.
    Human Physiology, 2016, 42 (8) : 898 - 904
  • [25] Huntington disease: natural history, biomarkers and prospects for therapeutics
    Ross, Christopher A.
    Aylward, Elizabeth H.
    Wild, Edward J.
    Langbehn, Douglas R.
    Long, Jeffrey D.
    Warner, John H.
    Scahill, Rachael I.
    Leavitt, Blair R.
    Stout, Julie C.
    Paulsen, Jane S.
    Reilmann, Ralf
    Unschuld, Paul G.
    Wexler, Alice
    Margolis, Russell L.
    Tabrizi, Sarah J.
    NATURE REVIEWS NEUROLOGY, 2014, 10 (04) : 204 - 216
  • [26] Huntington disease: natural history, biomarkers and prospects for therapeutics
    Christopher A. Ross
    Elizabeth H. Aylward
    Edward J. Wild
    Douglas R. Langbehn
    Jeffrey D. Long
    John H. Warner
    Rachael I. Scahill
    Blair R. Leavitt
    Julie C. Stout
    Jane S. Paulsen
    Ralf Reilmann
    Paul G. Unschuld
    Alice Wexler
    Russell L. Margolis
    Sarah J. Tabrizi
    Nature Reviews Neurology, 2014, 10 : 204 - 216
  • [27] Respiratory decline is integral to disease progression in Huntington's disease
    Jones, Una
    Busse, Monica
    Enright, Stephanie
    Rosser, Anne E.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (02) : 585 - 588
  • [28] PRELIMINARY DEVELOPMENT OF DISEASE PROGRESSION MODEL FOR HUNTINGTON'S DISEASE
    Sun, W.
    Hochhaus, G.
    Wang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S110 - S110
  • [29] Onset and pre-onset studies to define the Huntington's disease natural history
    Squitieri, F
    Cannella, M
    Giallonardo, P
    Maglione, V
    Mariotti, C
    Hayden, MR
    BRAIN RESEARCH BULLETIN, 2001, 56 (3-4) : 233 - 238
  • [30] Does the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Correlate with Disease Progression in Huntington's Disease?
    Smith, Haileigh
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 34 - 34